CRVO Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

4.070

Open

4.050

VWAP

3.92

Vol

56.64K

Mkt Cap

36.29M

Low

3.780

Amount

222.22K

EV/EBITDA(TTM)

--

Total Shares

9.26M

EV

16.36M

EV/OCF(TTM)

--

P/S(TTM)

9.07

CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.

Show More

Events Timeline

(ET)

2026-03-19

08:00:00

CervoMed Presents New Data on Neflamapimod at AD/PD 2026 Conference

2026-03-17 (ET)

2026-03-17

07:50:00

CervoMed Expects Cash to Fund Operations for Six Months

2026-03-12 (ET)

2026-03-12

07:30:00

CervoMed to Present Neflamapimod Research Progress at AD/PD 2026

2026-03-04 (ET)

2026-03-04

07:40:00

CervoMed Completes Phase 1 Study of Neflamapimod

2026-02-18 (ET)

2026-02-18

06:20:00

CervoMed's Oral Drug Neflamapimod Included in EXPERTS-ALS Platform

2025-12-04 (ET)

2025-12-04

17:10:00

CervoMed Reports Positive Results from Alzheimer's Clinical Trial

2025-12-02 (ET)

2025-12-02

07:10:00

CervoMed Reports Significant Reduction in Neurodegeneration Biomarker from Phase 2b RewinD-LB Trial

News

NASDAQ.COM

03-18NASDAQ.COM

CervoMed Reports 2025 Financial Results and Future Catalysts

seekingalpha

03-17seekingalpha

CervoMed Reports $27M Net Loss for FY with Revenue Beat

Newsfilter

03-04Newsfilter

CervoMed Advances Neflamapimod in Phase 3 Trial for Dementia

Newsfilter

02-18Newsfilter

CervoMed's Neflamapimod Approved for ALS Trials

Benzinga

Biotech Insider Buying Signals Strong, Three Companies Draw Attention

Globenewswire

2025-12-04Globenewswire

CervoMed's Neflamapimod Shows Significant Improvement in DLB Patients in Phase 2b Trial

5 Analyst Rating

Wall Street analysts forecast CRVO stock price to rise

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

19.00

Averages

22.75

High

27.00

Current: 0.000

Low

19.00

Averages

22.75

High

27.00

Chardan

Buy

upgrade

$15 -> $21

AI Analysis

2026-03-17

Reason

Chardan

Price Target

$15 -> $21

AI Analysis

2026-03-17

upgrade

Buy

Reason

Chardan raised the firm's price target on CervoMed to $21 from $15 and keeps a Buy rating on the shares. The neflamapimod program is fully back on track following alignment reached with the FDA in November 2025 for a Phase 3 registrational study in dementia with Lewy bodies, the analyst tells investors in a research note. With strong efficacy data with the new neflamapimod product batch in the completed Phase 2 study and with alignment on patient selection, a new drug formulation reaching desired drug plasma levels, and a new higher dose in the planned Phase 3 study, the firm is increasingly confident in the successful outcome of the DLB program.

Roth Capital

Boobalan Pachaiyappan

Buy

downgrade

$19 -> $11

2026-03-17

Reason

Roth Capital

Boobalan Pachaiyappan

Price Target

$19 -> $11

2026-03-17

downgrade

Buy

Reason

Roth Capital analyst Boobalan Pachaiyappan lowered the firm's price target on CervoMed to $11 from $19 and keeps a Buy rating on the shares. The company's Q4/FY25 financial results and corporate update were largely aligned with the firm's expectations, the analyst tells investors in a research note. While the company's 2H26 calendar is heavily loaded with multiple catalysts, the firm earnestly looks forward to Phase 3 Dementia with Lewy Bodies study initiation, given "solid" Phase 2 OLE study results and the first-mover advantage. The firm added that it cut its price target based on model updates reflecting the need to raise capital under less attractive terms.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CRVO

Unlock Now

Valuation Metrics

The current forward P/E ratio for CervoMed Inc (CRVO.O) is -3.46, compared to its 5-year average forward P/E of -5.70. For a more detailed relative valuation and DCF analysis to assess CervoMed Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-5.70

Current PE

-3.46

Overvalued PE

-2.21

Undervalued PE

-9.20

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-3.12

Current EV/EBITDA

-0.96

Overvalued EV/EBITDA

-0.09

Undervalued EV/EBITDA

-6.16

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

18.09

Current PS

44.41

Overvalued PS

30.09

Undervalued PS

6.09

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

can you limit the choices to only 5 stocks

Intellectia · 724 candidates

Price: <= $10.00Pe Ttm: <= 15Target Price Upside Potential: MoreAbovePrice

Ticker

Name

Market Cap$

Flux Power Holdings Inc

31.80M

Organogenesis Holdings Inc

487.34M

Sangamo Therapeutics Inc

127.97M

Aquestive Therapeutics Inc

409.93M

Traws Pharma Inc

19.42M

BTCS Inc

126.36M

Whales Holding CRVO

Trading Trends

People Also Watch

Frequently Asked Questions

What is CervoMed Inc (CRVO) stock price today?

The current price of CRVO is 3.92 USD — it has decreased -2.49

What is CervoMed Inc (CRVO)'s business?

CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.

What is the price predicton of CRVO Stock?

Wall Street analysts forecast CRVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRVO is22.75 USD with a low forecast of 19.00 USD and a high forecast of 27.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is CervoMed Inc (CRVO)'s revenue for the last quarter?

CervoMed Inc revenue for the last quarter amounts to 8.73K USD, decreased -99.60

What is CervoMed Inc (CRVO)'s earnings per share (EPS) for the last quarter?

CervoMed Inc. EPS for the last quarter amounts to -0.87 USD, increased 12.99

How many employees does CervoMed Inc (CRVO). have?

CervoMed Inc (CRVO) has 15 emplpoyees as of March 25 2026.

What is CervoMed Inc (CRVO) market cap?

Today CRVO has the market capitalization of 36.29M USD.